Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Sorrento Announces Drilling Contract & Receives Permit to Drill Bottom Brook Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News MultiCell Technologies Inc (EM) MCET

Healthcare Biotechnology
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a... see more

Current News (EXPM:MCET)

MultiCell Immunotherapeutics And Oxis Biotech Sign Antibody-Drug Conjugate R&D, Product License And Commercialization Agreement

PR Newswire March 12, 2015

MultiCell Technologies Files Novel Antibody-Drug Conjugate Patent Application

PR Newswire December 10, 2014

MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer

PR Newswire August 25, 2014

MultiCell Technologies Files U.S. and International Patent Applications for the Treatment of Liver Cancer

PR Newswire March 20, 2014

MultiCell Technologies Seeks Patent for Cancer-Fighting Technology

ACCESS Newswire March 4, 2014

MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics

PR Newswire January 15, 2014

MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of MCT-485, a Noncoding miRNA for Cancer Treatment

PR Newswire November 13, 2013

MultiCell Technologies Expands Scope of Research Agreement for the Treatment of Liver Cancer

PR Newswire October 2, 2013

MultiCell Technologies and Genisphere Evaluate Targeted Delivery of MCT-485, a Noncoding miRNA for the Treatment of Cancer

PR Newswire August 6, 2013
View More News ››

Opinion & Analysis (EXPM:MCET)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:MCET)

It is incomprehensible that MCET management refuses to file

It is incomprehensible that MCET management refuses to file with the SEC. It's ludicrous, that over 10 companies, one of which has 18...
MCETDREAMER - June 30, 2021

Sekisui XenoTech is Infringing on MCET Fa N2-4 Patent

Sekisui XenoTech Global Distribution Network has 18 distributors around the world illegally using the Fa N2-4 Immortalized human...
MCETDREAMER - June 29, 2021

Corporations Infringing on Multicell Technology Inc.

There are more Corporations Infringing on the Fa N2-4 immortalized Human Hepatocytes Cell Lines. This information doesn't include any...
MCETDREAMER - June 29, 2021

The latest company infringing on MCETs patent to come to the

Clonetech, Takara bio new to the market as of 2-26-2021 TAKAERA BIO WEBSITE: What's new Takara Bio USA, Inc. elevates the sensitivity...
MCETDREAMER - June 29, 2021

Multicell Technology inc Pre-Phase one potential lawsuit

Multicell Technology inc Pre-Phase one potential lawsuit. This is an exploratory investigation for a potential lawsuit to see if there...
MCETDREAMER - June 29, 2021

Interview with Steven Chang

President and CEO of Multicell Technologies, Inc. Steven Chang's interview is now online at Wall Street Reporter website
StockMaster1 - April 5, 2007
View more Bullboard ››

Allied Critical Metals Inc.

Allied Critical Metals Inc.

Allied Critical Metals (ACM:CSE) is a Canadian-based mining company focused on the expansion and revitalization of its 100 ...
View More »

Podcasts